This Article Full Text (PDF) All Versions of this Article: 0883073808324769v1 24/4/431    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dastgir, J. Articles by DiMario, F. J. Search for Related Content PubMed PubMed Citation Articles by Dastgir, J. Articles by DiMario, F. J., Jr Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE METHYLPREDNISOLONE Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Acute Tumefactive Demyelinating Lesions in a Pediatric Patient With Known Diagnosis of Multiple Sclerosis: Review of the Literature and Treatment Proposal

Department of Pediatrics, Division of Child Neurology, Connecticut Children's Medical Center, Hartford, Connecticut, fdimari{at}ccmckids.org

Francis J. DiMario, Jr, MD

University of Connecticut School of Medicine, Farmington, Connecticut

Tumefactive demyelinating lesions are a known but uncommon complication of multiple sclerosis, a disease rarely reported in children. This is the case of a 16-year-old African American patient with multiple sclerosis, who developed 2 tumefactive demyelinating lesions. Review of the literature and our own experience helped formulate an algorithm for therapeutic options during an acute attack.

Key Words: immunomodulator therapy • demyelinating disease • tumor

This version was published on April 1, 2009

Journal of Child Neurology, Vol. 24, No. 4, 431-437 (2009)
DOI: 10.1177/0883073808324769


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?